Profile data is unavailable for this security.
About the company
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-84.23m
- Incorporated2021
- Employees71.00
- LocationRezolute Inc275 Shoreline Drive, Suite 500REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 206-4507
- Fax+1 (302) 636-5454
- Websitehttps://www.rezolutebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 272.92m | 34.00 | -- | 10.48 | -- | 14.39 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| C4 Therapeutics Inc | 35.95m | -104.99m | 287.86m | 104.00 | -- | 1.11 | -- | 8.01 | -1.36 | -1.36 | 0.4337 | 2.65 | 0.1015 | -- | 13.06 | 345,644.20 | -29.63 | -27.16 | -33.31 | -30.47 | -- | -- | -292.08 | -328.00 | -- | -- | 0.00 | -- | 1.02 | 1.61 | 0.3058 | -- | -1.36 | -- |
| CytoDyn Inc | 0.00 | -40.35m | 293.46m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| TriSalus Life Sciences Inc | 40.21m | -72.25m | 295.47m | 110.00 | -- | -- | -- | 7.35 | -2.02 | -2.02 | 1.22 | -0.5357 | 1.26 | 1.76 | 8.11 | 365,518.20 | -123.81 | -- | -183.62 | -- | 84.04 | -- | -98.45 | -- | 2.75 | -6.61 | 5.43 | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| Rezolute Inc | 0.00 | -84.23m | 295.71m | 71.00 | -- | 2.31 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 296.86m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 298.38m | 275.00 | -- | 0.0325 | -- | 1.32 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 305.02m | 124.00 | -- | 1.80 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -33.85m | 307.53m | 8.00 | -- | 6.95 | -- | -- | -0.5637 | -0.5637 | 0.00 | 0.7355 | 0.00 | -- | -- | 0.00 | -38.32 | -33.16 | -51.97 | -37.60 | -- | -- | -- | -- | -- | -- | 0.2563 | -- | -- | -- | 39.40 | -- | -- | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 308.36m | 4.00 | -- | 1.38 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| Cabaletta Bio Inc | 0.00 | -158.52m | 312.86m | 148.00 | -- | 2.24 | -- | -- | -2.51 | -2.51 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -80.43 | -40.80 | -97.39 | -43.86 | -- | -- | -- | -- | -- | -- | 0.1371 | -- | -- | -- | -71.21 | -- | 26.12 | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 317.53m | 28.00 | -- | 1.79 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| KALA BIO Inc | 0.00 | -35.84m | 319.60m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Immuneering Corp | 0.00 | -62.50m | 319.62m | 54.00 | -- | 1.38 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
Data as of Mar 03 2026. Currency figures normalised to Rezolute Inc's reporting currency: US Dollar USD
68.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 31 Dec 2025 | 16.53m | 19.01% |
| RA Capital Management LPas of 31 Dec 2025 | 9.18m | 10.55% |
| Opaleye Management, Inc.as of 31 Dec 2025 | 6.29m | 7.23% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.76m | 6.62% |
| Balyasny Asset Management LPas of 31 Dec 2025 | 4.51m | 5.18% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.20m | 4.82% |
| BofA Securities, Inc.as of 31 Dec 2025 | 4.13m | 4.75% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.98m | 4.58% |
| UBS Securities LLCas of 31 Dec 2025 | 2.82m | 3.24% |
| Affinity Asset Advisors LLCas of 31 Dec 2025 | 2.35m | 2.70% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
